280 related articles for article (PubMed ID: 19242371)
1. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Westwood JA; Smyth MJ; Teng MW; Moeller M; Trapani JA; Scott AM; Smyth FE; Cartwright GA; Power BE; Hönemann D; Prince HM; Darcy PK; Kershaw MH
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19051-6. PubMed ID: 16365285
[TBL] [Abstract][Full Text] [Related]
3. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Peinert S; Prince HM; Guru PM; Kershaw MH; Smyth MJ; Trapani JA; Gambell P; Harrison S; Scott AM; Smyth FE; Darcy PK; Tainton K; Neeson P; Ritchie DS; Hönemann D
Gene Ther; 2010 May; 17(5):678-86. PubMed ID: 20200563
[TBL] [Abstract][Full Text] [Related]
4. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
5. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
[TBL] [Abstract][Full Text] [Related]
6. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
7. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
8. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
9. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine.
Kannagi R; Fukushi Y; Tachikawa T; Noda A; Shin S; Shigeta K; Hiraiwa N; Fukuda Y; Inamoto T; Hakomori S
Cancer Res; 1986 May; 46(5):2619-26. PubMed ID: 3008996
[TBL] [Abstract][Full Text] [Related]
10. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R
Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598
[TBL] [Abstract][Full Text] [Related]
11. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
Turatti F; Figini M; Balladore E; Alberti P; Casalini P; Marks JD; Canevari S; Mezzanzanica D
J Immunother; 2007 Oct; 30(7):684-93. PubMed ID: 17893561
[TBL] [Abstract][Full Text] [Related]
12. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
13. Genetic redirection of T cells for cancer therapy.
Westwood JA; Kershaw MH
J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
[TBL] [Abstract][Full Text] [Related]
14. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
15. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.
Heuser C; Hombach A; Lösch C; Manista K; Abken H
Gene Ther; 2003 Aug; 10(17):1408-19. PubMed ID: 12900755
[TBL] [Abstract][Full Text] [Related]
16. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells.
Dall P; Herrmann I; Durst B; Stoff-Khalili MA; Bauerschmitz G; Hanstein B; Niederacher D
Cancer Immunol Immunother; 2005 Jan; 54(1):51-60. PubMed ID: 15693139
[TBL] [Abstract][Full Text] [Related]
17. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
Lamers CH; Sleijfer S; Willemsen RA; Debets R; Kruit WH; Gratama JW; Stoter G
J Biol Regul Homeost Agents; 2004; 18(2):134-40. PubMed ID: 15471217
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
Eshhar Z
Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
[TBL] [Abstract][Full Text] [Related]
20. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
